VNDANGMHealthcare·Biotechnology#241 in industry

Vanda Pharmaceuticals Inc.

Reports in 10d· 2026-05-06

-15.4% · 90d

$6.79

-0.11 (-1.52%)

News

(1)

April 2026

Apr 23, 20264 days agoDEF 14AHealthcare

VNDA Proxy Details Cash Position, NEREUS Approval, and Key Pipeline Moves

VNDAVanda Pharmaceuticals Inc.

Here's a clear breakdown of Vanda Pharmaceuticals' DEF 14A proxy statement, explaining what it means for investors: # 📄 What This Document Is * This is the **Definitive Proxy Statement (DEF 14A)** for Vanda Pharmaceuticals' 2026 Annual Meeting of Stockholders. * It details the proposals stockh

Read summaryView on SEC EDGAR

Key Data

Market Cap$408.0M

Open$6.89

Prev Close$6.89

Day Range$6.79 – $7.18

52W Range$3.81 – $9.94

Volume1,056,769

P/E (TTM)—

EPS$-3.74

Dividend Yield—

Beta0.71

Profit Margin-102.02%

Revenue Growth7.60%

Price Target$15.50(+128.4%)

Next Earnings2026-05-06(10d)

Analyst Ratings

Strong Buy5 analysts

Buy 4Hold 1Sell 0

About

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Healthcare · Biotechnology

533 employees

www.vandapharma.com